Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

References

• Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm. 2011;26(1):1–17. doi:10.1089/cbr.2010.0902.
   PubMed Web of Science ®Google Scholar
• Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017;178:31–47. doi:10.1016/j.pharmthera.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94. doi:10.1038/nrclinonc.2017.166.
   PubMed Web of Science ®Google Scholar
• El-Sayes N, Vito A, Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers (Basel). 2021;13(4):806. doi:10.3390/cancers13040806.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber M, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92. doi:10.1056/NEJM198512053132327.
   PubMed Web of Science ®Google Scholar
• Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Diego LG, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12(6):673–84. doi:10.1517/14712598.2012.675323.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Toalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676–80. doi:10.1056/NEJM198812223192527.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PR, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2009;17(13):4550–7. doi:10.1158/1078-0432.CCR-11-0116.
   Web of Science ®Google Scholar
• June C, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. doi:10.1056/NEJMra1706169.
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7.
   PubMed Web of Science ®Google Scholar
• Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18(6):980–7. doi:10.1038/nm.2764.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li F, Sonnemann H, Jackson KR, Talukder AH, Katailiha AS, Lizee G. Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer. Cells. 2021;10(9):2379. doi:10.3390/cells10092379.
   PubMed Web of Science ®Google Scholar
• Hoover HC, Jr, Surdyke M, Dangel RB, Peters LC, Hanna MG. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res. 1984;44:1671–6.
   PubMed Web of Science ®Google Scholar
• Berd D, McGuire HC, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990;8(11):1858–67. doi:10.1200/JCO.1990.8.11.1858.
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D’Andre SD, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142. doi:10.1186/s12967-018-1507-6.
   PubMed Web of Science ®Google Scholar
• Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, et al. Audencel immunotherapy based on dendritic cells has no effect on overall and progression-free survival in newly diagnosed glioblastoma: a phase II randomized trial. Cancers. 2018;10(10):372. doi:10.3390/cancers10100372.
   PubMed Web of Science ®Google Scholar
• Tesatori A, Richards J, Whitman E, Mann B, Lutzky J, Camacho L, Pariani G, Tosti G, Kirkwood JM, Hoos A, et al. Phase III comparison of Vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 study group. J Clin Oncol. 2008;26(6):955–62. doi:10.1200/JCO.2007.11.9941.
   PubMed Web of Science ®Google Scholar
• Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kappor A, Vaena D, Lowrance W, Bratslavsky J, et al. Results of the ADAPT phase 3 study of rocalpuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2020;26(10):2327–36. doi:10.1158/1078-0432.CCR-19-2427.
   PubMed Web of Science ®Google Scholar
• Antonarelli G, Corti C, Tarantino P, Ascione L, Cortes J, Romero P, Mittendorf EA, Disis ML, Curigliano G. Therapeutic cancer vaccines revamping: technology advancements and pitfalls. Ann Oncol. 2021;32:1537–51.
   PubMed Web of Science ®Google Scholar
• Bansal N, Banerjee D. Tumor initiating cells. Curr Pharm Biotechnol. 2009;10(2):192–6. doi:10.2174/138920109787315015.
   PubMed Web of Science ®Google Scholar
• Qureshi-Baig K, Ullmann P, Haan S, Letellier E. Tumor-initiating cells: a mmunel review of isolation approaches and new challenges in targeting strategies. Mol Cancer. 2017;16(1):40. doi:10.1186/s12943-017-0602-2.
   PubMedGoogle Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–6. doi:10.1038/nature14426.
   PubMed Web of Science ®Google Scholar
• Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res. 2016;22(8):1885–96. doi:10.1158/1078-0432.CCR-15-1509.
   PubMed Web of Science ®Google Scholar
• Balan S, Finnigan J, Bhardwaj N. Dendritic cell strategies for eliciting mutation-derived tumor antigen responses in patients. Cancer J. 2017;23(2):131–7. doi:10.1097/PPO.0000000000000251.
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–60. doi:10.1126/science.aar7112.
   PubMed Web of Science ®Google Scholar
• Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619–29. doi:10.1038/s41591-022-01937-6.
   PubMed Web of Science ®Google Scholar
• West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer. 2010;102(10):1519–23. doi:10.1038/sj.bjc.6605674.
   PubMed Web of Science ®Google Scholar
• Smits AJJ, Kummer JA, de Bruin PC, Bol M, van den Tweel JG, Seldenrijk KA, Willems SM, Offerhaus GJA, de Weger RA, van Diest PJ, et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol. 2014;27(2):168–74. doi:10.1038/modpathol.2013.134.
   PubMed Web of Science ®Google Scholar
• Wu J, Liang C, Chen M, Su W. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Oncotarget. 2016;7(42):68954–65. doi:10.18632/oncotarget.12135.
   PubMedGoogle Scholar
• Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21(1):208. doi:10.1186/s12943-022-01670-1.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840. doi:10.3390/ijms20040840.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11. doi:10.1038/35102167.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253–61. doi:10.1056/NEJMra061808.
   PubMed Web of Science ®Google Scholar
• Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12(2):133–43. doi:10.1038/nrc3184.
   PubMed Web of Science ®Google Scholar
• Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. Faseb J. 2013;27(1):13–24. doi:10.1096/fj.12-218222.
   PubMed Web of Science ®Google Scholar
• Abbaszadegan MR, Bagheri V, Razavi MS, Momtazi AA, Sahebkar A, Gholamin M. Isolation, identification, and characterization of cancer stem cells: a review. J Cell Physiol. 2017;232(8):2008–18. doi:10.1002/jcp.25759.
   PubMed Web of Science ®Google Scholar
• Oldham RK, Dillman RO, Yannelli JR, Barth NM, Maleckar JR, Sferruzza A, Cohen RJ, Minor DR, Spitler L, Birch R, et al. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a national biotherapy study group trial. Mol Biother. 1991;68(1):68–73. doi:10.1002/1097-0142(19910701)68:1<1:AID-CNCR2820680102>3.0.CO;2-K.
   Google Scholar
• Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Maleckar JR, Yannelli JR, Sferruzza A, Arnold J, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer. 1991;68(1):1–8. doi:10.1002/1097-0142(19910701)68:1<1:AID-CNCR2820680102>3.0.CO;2-K.
   PubMed Web of Science ®Google Scholar
• Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology. 2014;28:1101–7.
   PubMed Web of Science ®Google Scholar
• Zhou L, Lu L, Wicha MS, Chang AE, Xia JC, Ren X, Li Q. Promise of cancer stem cell vaccine. Hum Vaccines Immunother. 2015;11(12):2796–9. doi:10.1080/21645515.2015.1083661.
   PubMed Web of Science ®Google Scholar
• Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11(1):47–76. doi:10.1146/annurev-pathol-012615-044438.
   PubMedGoogle Scholar
• Codd AS, Kanaseki T, Torigo T, Zsuzsanna T. Cancer stem cells as targets for immunotherapy. Immunology. 2017;153(3):304–14. doi:10.1111/imm.12866.
   PubMed Web of Science ®Google Scholar
• Atashzar MR, Baharlou R, Karami J, Abdollahi H, Rezaei R, Pourramezan F, Zoljalali Moghaddam SH. Cancer stem cells: a review from origin to therapeutic implications. J Cell Physiol. 2020;235(2):790–803. doi:10.1002/jcp.29044.
   PubMed Web of Science ®Google Scholar
• Maccalli C, Rasul KI, Elawad M, Ferrone S. The role of cancer stem cells in the modulation of anti-tumor immune responses. Semin Cancer Biol. 2018;53:189–200. doi:10.1016/j.semcancer.2018.09.006.
   PubMed Web of Science ®Google Scholar
• Chen P, Hsu WH, Han J, Xia Y, DePinho RA. Cancer stemness meets immunity: from mechanism to therapy. Cell Rep. 2021;34(1):108597. doi:10.1016/j.celrep.2020.108597.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Ward JP, Gubin MM, Schreiber RD. The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol. 2016;130:25–74.
   PubMed Web of Science ®Google Scholar
• Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853–64. doi:10.1158/0008-5472.CAN-11-1400.
   PubMed Web of Science ®Google Scholar
• Lu L, Tao H, Chang AE, Hu Y, Shu G, Chen Q, Egenti M, Owen J, Moyer JS, Prince ME. Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncoimmunology. 2015;4(3):e990767. doi:10.4161/2162402X.2014.990767.
   PubMed Web of Science ®Google Scholar
• Dashti A, Ebrahimi M, Hadjati J, Memarnejadian A, Moazzeni SM. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. Cancer Lett. 2016;374(1):175–85. doi:10.1016/j.canlet.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V, Sato N. Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci. 2016;107(1):12–17. doi:10.1111/cas.12830.
   PubMed Web of Science ®Google Scholar
• So JY, Suh N. Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol. 2015;148:79–85. doi:10.1016/j.jsbmb.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Bradshaw A, Wickremsekera A, Tan ST, Peng L, Davis PF, Itinteang T. Cancer stem cell hierarchy in glioblastoma multiforme. Front Surg. 2016;3:21. doi:10.3389/fsurg.2016.00021.
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68(11):4311–20. doi:10.1158/0008-5472.CAN-08-0364.
   PubMed Web of Science ®Google Scholar
• Parmiani G. Melanoma cancer stem cells: markers and functions. Cancers (Basel). 2016;8(3):34. doi:10.3390/cancers8030034.
   PubMed Web of Science ®Google Scholar
• Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56–8.
   PubMed Web of Science ®Google Scholar
• De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63(1):12–17.
   PubMed Web of Science ®Google Scholar
• Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol. 2003;171(11):6275–82. doi:10.4049/jimmunol.171.11.6275.
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med. 2004;2(1):27. doi:10.1186/1479-5876-2-27.
   PubMedGoogle Scholar
• Martin-Fontecha A, Lanzavecchia A, Sallusto F. Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol. 2009;188:31–49.
   Google Scholar
• Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JF, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15(7):2531–40. doi:10.1158/1078-0432.CCR-08-2729.
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res. 2013;19(6): 1525-1523. doi:10.1158/1078-0432.CCR-12-1879.
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69. doi:10.1038/nri3254. Campana S, De Pasquale C, Carrega P, Ferlazzo G, Bonaccorsi I. Cross-dressing: an alternative mechanism for antigen presentation. Immunol Letters 2015;168:349-354.
   PubMed Web of Science ®Google Scholar
• Van Endert P. Intracellular recycling and cross-presentation by MHC class I molecules. Immuno Rev. 2016;272(1):80–96. doi:10.1111/imr.12424.
   PubMed Web of Science ®Google Scholar
• Colbert JD, Cruz F, Rock KL. Cross-presentation of exogenous antigens on MHCI molecules. Curr Opin Immunol. 2020;64:1–8. doi:10.1016/j.coi.2019.12.005.
   PubMed Web of Science ®Google Scholar
• MacNabb BW, Chen X, Tumuluru S, Godfrey J, Kasal DN, Yu J, Jongsma ML, Spaapen R, Kline DE, Kline J. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55:982–97. doi:10.1016/j.immuni.2022.04.016.
   PubMed Web of Science ®Google Scholar
• Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67–124.
   PubMed Web of Science ®Google Scholar
• Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–12. doi:10.1172/JCI80009.
   PubMed Web of Science ®Google Scholar
• Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immune-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. doi:10.1186/s13045-022-01247-x.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Hsieh C, Nistor GI. A clinical odyssey: cancer stem cells as the antigen source for autologous cancer vaccines. Adv Stem Cell Res. 2019;1:1–13.
   Google Scholar
• Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother Emphasis Tumor Immunol. 1993;14(1):65–9. doi:10.1097/00002371-199307000-00009.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nayak SK, Brown JV, Mahdavi K, Beutel LD. The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer. Cancer Biother Radiopharm. 1999;14(6):443–9. doi:10.1089/cbr.1999.14.443.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Beutel LD, Cornforth AN, Nayak SK. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Cancer Biother Radiopharm. 2000;15(2):161–8. doi:10.1089/cbr.2000.15.161.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, Beutel LD, de Leon C, DePriest C, Nayak S. Autologous tumor cell line–derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004;19(5):570–80. doi:10.1089/1084978042484786.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Barth NM, Selvan SR, Beutel LD, Depriest C, de Leon C, Peterson C, Nayak S. Phase I/II trial of autologous tumor cell line–derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004;19(5):581–8. doi:10.1089/1084978042484812.
   PubMed Web of Science ®Google Scholar
• Dillman RO, DePriest C, DeLeon C, Barth NM, Schwartzberg LS, Beutel LD, Schiltz PM, Nayak SK. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm. 2007;22(3):309–21. doi:10.1089/cbr.2007.345.
   PubMed Web of Science ®Google Scholar
• Haspel MV, McCabe RP, Pomato N, Janesch NJ, Knowlton JV, Peters LC, Hoover HC, Jr, Hanna MC, Jr. Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res. 1985;45:1236–43.
   Google Scholar
• Hoover HC, Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG, Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 1985;55:1236–43.
   PubMed Web of Science ®Google Scholar
• Nayak SK, Schiltz PM, Dillman RO. Modulation of renal carcinoma cells in vitro: comparison after transduction with retroviral vector containing a human γ-interferon gene versus incubation with soluble γ-interferon. J Interferon Cytokine Res. 1999;19(1):49–58. doi:10.1089/107999099314414.
   PubMed Web of Science ®Google Scholar
• González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccines Immunother. 2014;10(11):3261–9. doi:10.4161/21645515.2014.982996.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, McClay EF, Depriest C. Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Manag. 2019 31;6(2):MMT20. doi:10.2217/mmt-2018-0010.
   PubMed Web of Science ®Google Scholar
• Geskin LJ, Damiano JJ, Patrone CC, Butterfield LH, Kirkwood JM, Falo LD. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018;28(3):211–21. doi:10.1097/CMR.0000000000000441.
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013–18. doi:10.1073/pnas.0500090102.
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22(4):807–12. doi:10.1158/1078-0432.CCR-14-3175.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Rosenberg SA. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255–62. doi:10.1038/ni.3682.
   PubMed Web of Science ®Google Scholar
• Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. Ann Transl Med. 2016;4(14):262. doi:10.21037/atm.2016.06.17.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Med. 2013;19(6):747–52. doi:10.1038/nm.3161.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):3401–10. doi:10.1158/1078-0432.CCR-14-0433.
   PubMed Web of Science ®Google Scholar
• Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis. 2022;39(1):51–60. doi:10.1007/s10585-021-10091-1.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi S, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. doi:10.1200/JCO.2014.56.2736.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30. doi:10.1200/JCO.2013.53.0105.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised controlled, open-label phase 3 trial. Lancet Oncol. 2015;16(4):375–84. doi:10.1016/S1470-2045(15)70076-8.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. doi:10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-0002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18. doi:10.1016/S1470-2045(15)00083-2.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223–49. doi:10.1146/annurev-pathol-042020-042741.
   PubMed Web of Science ®Google Scholar
• Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–8. doi:10.1126/science.aaa3828.
   PubMed Web of Science ®Google Scholar
• Vormehr M, Diken M, Boegel S, Kreiter S, Türeci Ö, Sahin U. Mutanome directed cancer immunotherapy. Curr Opin Immunol. 2016;39:14–22. doi:10.1016/j.coi.2015.12.001.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77. doi:10.1038/nrc3258.
   PubMed Web of Science ®Google Scholar
• Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1(3):145–9. doi:10.1158/2326-6066.CIR-13-0102.
   PubMed Web of Science ®Google Scholar
• Bonaccorsi I, Campana S, Morandi B, Ferlazzo G. Acquisition and presentation of tumor antigens by dendritic cells. Crit Rev Immunol. 2015;35(5):349–64. doi:10.1615/CritRevImmunol.v35.i5.10.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Nistor GI. Dendritic cell vaccines for melanoma: past, present, and future. Melanoma Manag. 2016;3(4):273–89. doi:10.2217/mmt-2016-0014.
   PubMedGoogle Scholar
• Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65(4):798–810. doi:10.1007/s12026-017-8931-1.
   PubMed Web of Science ®Google Scholar
• de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, et al. Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. Melanoma Res. 2017;27(4):351–7. doi:10.1097/CMR.0000000000000356.
   PubMed Web of Science ®Google Scholar
• Linnette GP, Carreno BM. On the twentieth anniversary of dendritic cell vaccines – riding the next wave. Cancer Res. 2022;82(6):966–8. doi:10.1158/0008-5472.CAN-21-4440.
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9(1):271–96. doi:10.1146/annurev.iy.09.040191.001415.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Decisions about dendritic cells: past, present, and future. Ann Rev Immunol. 2012;30(1):1–22. doi:10.1146/annurev-immunol-100311-102839.
   PubMedGoogle Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109–18. doi:10.1084/jem.179.4.1109.
   PubMed Web of Science ®Google Scholar
• Feuerstein B, Berger TG, Maczek C, Röder C, Schreiner D, Hirsch U, Haendle I, Leisgang W, Glaser A, Kuss O, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods. 2000;245(1–2):15–29. doi:10.1016/S0022-1759(00)00269-6.
   PubMed Web of Science ®Google Scholar
• Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med. 2000;191(10):1699–708. doi:10.1084/jem.191.10.1699.
   PubMed Web of Science ®Google Scholar
• Zhang R, Yuan F, Shu Y, Tian Y, Zhou B, Yi L, Zhang X, Ding Z, Xu H, Yang L. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunol Immunother. 2020;69(1):135–45. doi:10.1007/s00262-019-02448-z.
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells. Nat Med. 1996;2(1):52–8. doi:10.1038/nm0196-52.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328–32. doi:10.1038/nm0398-328.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM, Peterson C, Allen K, DePriest C, McClay E, Barth N, Sheehy P, de Leon C, et al. Phase I/II trial of melanoma patient–specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm. 2004;19(5):658–65. doi:10.1089/1084978042484759.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM. Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med. 2006;355(11):1179–81. doi:10.1056/NEJMc061667.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma. Final Rep Cancer Biother Radiopharm. 2009;24(3):311–9. doi:10.1089/cbr.2008.0599.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother (1991). 2012;35(8):641–9. doi:10.1097/CJI.0b013e31826f79c8.
   PubMed Web of Science ®Google Scholar
• Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. Methods Mol Biol. 2013;969:111–25.
   PubMedGoogle Scholar
• Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol. 2015;111(7):862–7. doi:10.1002/jso.23897.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Depriest C. Dendritic cell vaccines presenting autologous tumor antigens from self-renewing cancer cells in metastatic renal cell cancer. J Exploratory Res Pharmacol. 2018;3(4):93–101. doi:10.14218/JERP.2018.00012.
   Google Scholar
• Dillman RO, Cornforth AN, Nistor GI, McClay EF, Amatruda TT, Depriest C. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. J ImmunoTher Cancer. 2018;6(1):19. doi:10.1186/s40425-018-0330-1.
   PubMed Web of Science ®Google Scholar
• Bota DA, Taylor TH, Piccioni DE, Duma CM, LaRocca RV, Kesari S, Carrillo JA, Abedi M, Aiken RD, Hsu FPK, et al. Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed glioblastoma patients: safety and efficacy assessment. J Exp Clin Cancer Res. 2022;41(1):344. doi:10.1186/s13046-022-02552-6.
   PubMed Web of Science ®Google Scholar
• Eskander RN, Abaid LN, Corr BR, Mason JR, Cappuccini F, Friedman RL, Robles RM, Lopez KL, Nistor GI, Dillman RO Tumor collection and establishment of tumor-initiating cell cultures to serve as the antigen source for AV-OVA-1 dendritic cell vaccines for patients with newly diagnosed advanced ovarian cancer. Poster presented at: the 37th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC); 2022 Nov 8-12; Boston, MA.
   Google Scholar
• Flanigan RC, Polcari AJ, Shore ND, Price TH, Sims RB, Maher JC, Whitmore JB, Corman JM. An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of sipuleucel-T for metastatic castrate resistant prostate cancer. J Urol. 2013;189(2):521–6. doi:10.1016/j.juro.2012.09.029.
   PubMed Web of Science ®Google Scholar
• Mason JR, Abaid LN, Corr BR, Eskander RN, Cappuccini F, Friedman RL, Robles RM, Lopez KL, Nistor GI, Dillman RO Leukapheresis to obtain monocytes to produce dendritic cells for manufacturing AV-OVA-1 personal vaccines in a randomized phase II trial in patients with newly diagnosed advanced ovarian cancer. Poster presented at: the 37th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC); 2022 Nov 8-12; Boston, MA.
   Google Scholar
• Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L. Active-specific immunotherapy for melanoma. J Clin Oncol. 1990;8(5):856–69. doi:10.1200/JCO.1990.8.5.856.
   PubMed Web of Science ®Google Scholar
• Cole IJ, Gruber J. Progress and prospects for human cancer vaccines. J Natl Cancer Inst. 1992;84(1):18–23. doi:10.1093/jnci/84.1.18.
   PubMedGoogle Scholar
• Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res. 1995;139:337–48.
   PubMedGoogle Scholar
• Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992;216(4):463–82. doi:10.1097/00000658-199210000-00010.
   PubMed Web of Science ®Google Scholar
• Weiner LM. Applications of gamma-interferon in cancer therapy. Mol Biother. 1991;3:186–91.
   PubMedGoogle Scholar
• Fagerberg J. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol. 1996;13:155–60.
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Darrah D, Stevenson L. Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa. Cancer Invest. 2002;20(5–6):759–68. doi:10.1081/CNV-120002493.
   PubMed Web of Science ®Google Scholar
• Obeid J, Hu Y, Slingluff CL. Vaccines, adjuvants, and dendritic cell activators—current status and future challenges. Semin Oncol. 2015;42(4):549–61. doi:10.1053/j.seminoncol.2015.05.006.
   PubMed Web of Science ®Google Scholar
• Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28(7):329–38. doi:10.1093/intimm/dxw015.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Interferon-gamma or granulocyte macrophage colony stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase II trial of the cancer biotherapy research group. J Immunother (1991). 2003;26(4):367–73. doi:10.1097/00002371-200307000-00009.
   PubMed Web of Science ®Google Scholar
• Schrader JW. Peptide regulatory factors and optimization of vaccines. Mol Immunol. 1991;28(3):295–9. doi:10.1016/0161-5890(91)90077-W.
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90(8):3539–43. doi:10.1073/pnas.90.8.3539.
   PubMed Web of Science ®Google Scholar
• Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 1996;88(1):202–10. doi:10.1182/blood.V88.1.202.202.
   PubMed Web of Science ®Google Scholar
• Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol. 2000;7(3):168–73. doi:10.1097/00062752-200005000-00007.
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor–secreting tumor vaccine for pancreatic cancer: a phase i trial of safety and immune activation. J Clin Oncol. 2001;19(1):145–56. doi:10.1200/JCO.2001.19.1.145.
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355–66. doi:10.1084/jem.190.3.355.
   PubMed Web of Science ®Google Scholar
• Li B, VanRoey M, Wang C, Chen TT, Korman A, Joos K. Anti–programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res. 2009;15(5):1623–34. doi:10.1158/1078-0432.CCR-08-1825.
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21(21):4016–26. doi:10.1200/JCO.2003.10.005.
   PubMed Web of Science ®Google Scholar
• Van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood. 2012;110(15):3383–93. doi:10.1182/blood-2011-11-370130.
   Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ. Adjuvant therapy of stage III and IV malignant melanoma using granulocytes-macrophage colony-stimulating factor. J Clin Oncol. 2000;18(8):1614–21. doi:10.1200/JCO.2000.18.8.1614.
   PubMed Web of Science ®Google Scholar
• Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, Lin H, Soong SJ. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of states II(T4), III, and IV melanoma. J Immunother. 2009;32(6):632–7. doi:10.1097/CJI.0b013e3181a7d60d.
   PubMed Web of Science ®Google Scholar
• Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, et al. Randomized, placebo-controlled, phase III trial of yeast-derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the eastern cooperative oncology group-American college of radiology imaging network cancer research group (E4697). J Clin Oncol. 2015;33(34):4066–74. doi:10.1200/JCO.2015.62.0500.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. doi:10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Collichio F, Harrington KJ, Middleton M, Dosney G, Öhrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J ImmunoTher Cancer. 2019;7(1):145. doi:10.1186/s40425-019-0623-z.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. J ImmunoTher Cancer. 2014;2(1):11. doi:10.1186/2051-1426-2-11.
   PubMedGoogle Scholar
• Dillman RO. An update on GM-CSF and its potential role in melanoma management. Melanoma Manag. 2020;7(3):MMT49. doi:10.2217/mmt-2020-0011.
   PubMed Web of Science ®Google Scholar
• Abaid LN, Corr BR, Mason JR, Eskander RN, Cappuccini F, Friedman RL, Lopez KL, Nistor GI, Dillman RO Treatment-related adverse events in a randomized trial in stage 3 and 4 ovarian cancer testing patient-specific dendritic cell vaccines loaded with tumor antigens from self-renewing autologous ovary cancer cells. Poster presented at: the 2023 Society of Gynecologic Oncology Annual Meeting; 2023 Mar 25-28; Tampa Bay, FL.
   Google Scholar
• Dillman RO, Cornforth AN, Depriest C. Cancer stem cell antigens from autologous tumor cell lines in patient-specific active immunotherapy for metastatic cancer. In: Hayat M editor. Chapter 26 in stem cells and cancer stem cells. Vol. 9. London, England: Springer; 2013. pp. 272–84.
   Google Scholar
• Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res. 2010;20(4):280–92. doi:10.1097/CMR.0b013e3283390696.
   PubMed Web of Science ®Google Scholar
• Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. Clin Biotechnol. 1991;3:237–42.
   Google Scholar
• Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and Antitumor effects of vaccination with peptide vaccine +/− granulocyte-monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern cooperative oncology group phase II trial E1696. Clin Cancer Res. 2009;15(4):1443–51. doi:10.1158/1078-0432.CCR-08-1231.
   PubMed Web of Science ®Google Scholar
• Slota M, Lim JB, Dang Y, Disis ML. Elispot for measuring human immune responses to vaccines. Expert Rev Vaccines. 2011;10(3):299–306. doi:10.1586/erv.10.169.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, et al. Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697). Clin Cancer Res. 2017;23(17):5034–43. doi:10.1158/1078-0432.CCR-16-3016.
   PubMed Web of Science ®Google Scholar
• Nistor GI, Dillman RO, Robles RM, Langford JL, Poole AJ, Sofro MAU, Nency YM, Jonny J, Yana ML, Karyana M, et al. A personal COVID-19 dendritic cell vaccine made at point-of-care: feasibility, safety, and antigen-specific cellular immune responses. Hum Vaccines Immunother. 2022;18(6):2100189. doi:10.1080/21645515.2022.2100189.
   PubMed Web of Science ®Google Scholar
• Nistor GI, Dillman RO. Cytokine network analysis of immune responses before and after therapeutic vaccine immunotherapies in a randomized trial in patients with metastatic melanoma. J Transl Med. 2020;18(1):176. doi:10.1186/s12967-020-02328-6.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Unpublished observation NCT02033616.
   Google Scholar
• Cornforth AN, Lee GJ, Fowler AW, Carbonell DJ, Dillman RO. Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. Clin Immunol. 2009;29(5):657–64. doi:10.1007/s10875-009-9299-3.
   Web of Science ®Google Scholar
• Vissers JL, Hartgers FC, Lindhout E, Teunissen MB, Figdor CG, Adema GJ. Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo. J Leukoc Biol. 2001;69(5):785–93. doi:10.1189/jlb.69.5.785.
   PubMed Web of Science ®Google Scholar
• Achuthan A, Cook AD, Lee MC, Saleh R, Khiew HW, Chang MW, Louis C, Fleetwood AJ, Lacey DC, Christensen AD, et al. Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J Clin Invest. 2016;126(9):3453–66. doi:10.1172/JCI87828.
   PubMed Web of Science ®Google Scholar
• Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(Suppl 2):19–21. doi:10.1634/theoncologist.13-S2-19.
   PubMed Web of Science ®Google Scholar
• Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definite endpoint in cancer clinical trials. Cancer J. 2009;15(5):401–5. doi:10.1097/PPO.0b013e3181bdc2e0.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. doi:10.1093/jnci/92.3.205.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials. Cancer Biother Radiopharm. 1996;11(2):99–104. doi:10.1089/cbr.1996.11.99.
   PubMed Web of Science ®Google Scholar
• Korn RL, Crowley JJ. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res. 2013;19(10):2607–12. doi:10.1158/1078-0432.CCR-12-2934.
   PubMed Web of Science ®Google Scholar
• Salazar LG, Disis ML. Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol. 2005;23(30):7397–8. doi:10.1200/JCO.2005.07.020.
   PubMed Web of Science ®Google Scholar
• Kim SI, Cassella CR, Byrne KT. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes. Front Immunol. 2021;11:629722. doi:10.3389/fimmu.2020.629722.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nanci AA, Williams ST, Kim RB, Hafer RL, Coleman CL, Wang PC, Duma CM, Chen PV, Selvan SR, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm. 2010;25(5):553–7. doi:10.1089/cbr.2010.0819.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nistor GI, Poole AJ. Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine. Hum Vaccines Immunother. 2020;16(4):742–55. doi:10.1080/21645515.2019.1680239.
   PubMed Web of Science ®Google Scholar
• Piccioni DE, Duma CM, Kesari S, LaRocca RV, Aiken RD, Taylor TH, Carrillo JA, Abedi M, Nistor GI, Keirstead HS, et al. Progression free survival in a phase 2 trial of personal dendritic cell vaccines in patients with newly diagnosed glioblastoma. J Clin Oncol Res Ther. 2022;7:10149.
   Google Scholar
• Dillman RO. Long-term progression free and overall survival in two melanoma patients treated with patient-specific therapeutic vaccine eltrapuldencel-T after resection of a solitary liver metastasis. Cancer Biother Radiopharm. 2016;31(3):71–4. doi:10.1089/cbr.2016.2003.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Patient-specific therapeutic vaccines for metastatic melanoma. Oncol Iss. 2015 Mar-Apr;30(2):48–57. doi:10.1080/10463356.2015.11884014.
   Google Scholar
• Javed A, Sato S, Sato T. Autologous melanoma cell vaccine using monocyte-derived dendritic cells (Nbs20/eltrapuldencel-T). Future Oncol. 2016;12(6):751–62. doi:10.2217/fon.16.13.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Is vaccine research still relevant for metastatic melanoma? Melanoma Manag. 2014;1(2):91–4. doi:10.2217/mmt.14.18.
   PubMedGoogle Scholar
• Dillman RO. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccines Immunother. 2017;13(3):528–32. doi:10.1080/21645515.2016.1244149.
   PubMed Web of Science ®Google Scholar
• Collins JM, Redman JM, Gulley JL. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate tumor immunotherapy. Exp Rev Vaccines. 2018;17(8):697–705. doi:10.1080/14760584.2018.1506332.
   PubMed Web of Science ®Google Scholar
• Schlom J, Gulley JL. Vaccines as an integral component of cancer immunotherapy. JAMA. 2018;320(21):2195–6. doi:10.1001/jama.2018.9511.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–37. doi:10.1016/j.cell.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–8. doi:10.1200/JCO.2010.30.5425.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. doi:10.1126/scitranslmed.3003689.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012;72(13):3125–30. doi:10.1158/0008-5472.CAN-11-4094.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 expression and associated T-cell Infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015;21(13):3052–60. doi:10.1158/1078-0432.CCR-14-3073.
   PubMed Web of Science ®Google Scholar
• Das S, Camphausen K, Shankavaram U. Cancer-specific immune prognostic signature in solid tumors and Its relation to immune checkpoint therapies. Cancers (Basel). 2020;12(9):2476. doi:10.3390/cancers12092476.
   PubMed Web of Science ®Google Scholar
• Frederico SC, Hancock JC, Brettschneider EES, Ratnam NM, Gilbert MR, Terabe M. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front Oncol. 2021;11:672508. doi:10.3389/fonc.2021.672508.
   PubMed Web of Science ®Google Scholar
• Ullman NA, Burchard PR, Dunne RF, Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40(24):2789–805. doi:10.1200/JCO.21.02616.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27. doi:10.1056/NEJMoa1012863.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Depriest C, McClure SE. High-dose IL-2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm. 2014;29(2):53–7. doi:10.1089/cbr.2013.1565.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nistor GI, McLelland BT, Hsieh C, Poole AJ, Cornforth AN, Keirstead HS. Preliminary observations on soluble programmed death protein-1 (sPD1) as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines. Oncotarget. 2019;10(51):5359–71. doi:10.18632/oncotarget.27164.
   PubMedGoogle Scholar
• Dillman RO. Unpublished observation. NCT03400917
   Google Scholar